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OBJECTIVES: The number of deaths from vascular diseases is incredibly high worldwide, and reliable markers for
major events are still needed. The current cross-sectional study investigated the association of Klotho
haplotypes and Klotho serum levels with classic risk factors and a clinical history of vascular events.
METHODS: Clinical, anthropometric, biochemical and nutritional assessments were conducted with 168 older
adults, complemented by genotyping (rs9536314 and rs9527025) and the detection of serum Klotho (ELISA).
RESULTS: Klotho levels and haplotypes did not associate with most classic risk factors for vascular events,
including markers such as C-reactive protein and homocysteine. A positive association was only found between
Klotho levels and the previous occurrence of a myocardial infarction by both correlational (p=0.006) and
variance analyses (po0.001), and these associations were independent of the context.
CONCLUSION: Our results suggest that serum Klotho is higher in individuals with a clinical history of myocardial
infarction but not with a history of coronary artery disease or stroke. None of the Klotho haplotypes were
associated with the variables investigated herein.
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’ INTRODUCTION
Globally, vascular diseases accounted for 17.5 million deaths
in 2012. Coronary artery disease (CAD) is the single most
frequent cause of death worldwide, accounting for 12.8% of
all deaths (over 7 million), whereas cerebrovascular events
accounted for 11.9% of the same total (1). As the major
finding associated with vascular events, atherosclerosis is a
chronic/progressive, focal process with multifactorial etiology
(genetic and lifestyle) that co-occurs with systemic disorders
that share hormonal and inflammatory determinants (2) that
may have an early age of onset but only manifest later in
life (3,4). Atherosclerosis occurs in more than 50% of the
westernized adult population worldwide (5,6).
In this context, CAD is characterized by the narrowing of
the walls of coronary arteries (stenosis), which reduces the
blood flow to the heart muscle and is mostly caused by the
accumulation of atheromatous plaques due to common risk
factors such as poor diet, smoking, family history and genetic
factors. As a possible outcome, a myocardial infarction (MI)
damages the cardiac tissue, with a diagnosis set by the marked
elevation of serum indicators (preferably troponin), accom-
panied by clinical aspects such as symptoms suggestive of
ischemia, new Q waves on electrocardiography, or imaging
evidence of viable myocardium or ventricular contractility
losses (7).
Regarding cerebrovascular diseases, 90% result from lesions
of the carotid arteries (8,9), which can lead to cerebral vascular
accidents (strokes) due to the sudden closure or rupture of
the arterial or venous vasculature of the brain (10). Regard-
less of whether the injury is hemorrhagic or ischemic (the latter
is defined as an acute dysfunction in arterial territory (11)),
brain damage can result from an acute thrombotic event and
can manifested as hemiplegia, aphasia or seizures (12). No
serum marker is currently available to specifically predict the
risk of the occurrence of vascular events in the brain.
The most important factors that are commonly assessed
in clinical settings and are suggestive of vascular events
in general include circulating levels of homocysteine and
C-reactive protein (CRP), in addition to levels of lipoproteins
and a few other markers. Both homocysteine and CRP tend
to be present at high concentrations in individuals who are atDOI: 10.6061/clinics/2016(12)09
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increased risk of vascular events (13). Although CRP predicts
CAD-related events independently of other risk factors
(14-16), its levels can also be transiently increased over 2 to
3 weeks due to a serious infection, trauma or extra-cardiac
ischemic event (17), which can compromise a safe clinical
evaluation based on these markers. Additionally, circula-
ting homocysteine is negatively correlated with the intake
of vitamins as B6, B12 and folate (18-21) and is therefore
nutritionally biased. Chronic renal failure may also interfere
with breakdown of this biomarker, leading to hyperhomo-
cysteinemia (22). Thus, the low specificity of the markers
considered so far highlights the need for new, reliable bio-
markers for vascular disorders (23), with studies in both
clinical and experimental contexts taking place worldwide
in search of candidates that are less susceptible to inter-
ference by associated comorbidities or lifestyle factors.
However, many molecular aspects in the development
of atherosclerosis, CAD, MI and stroke remain unknown,
which reveals an open field for studies to identify new
factors of great value for elaborating clinical procedures for
primary prevention or assessing subsequent stages.
Thus, the Klotho protein is a potential marker for vascular
events. Suppressing the Klotho gene in animal models causes
extensive phenotypes similar to those of the aging pheno-
type, including atherosclerosis, ectopic calcification, inferti-
lity, skin atrophy and severe hypoglycemia (24), while its
overexpression increases the total life span of guinea pigs by
20 to 30% (25). These phenotypes led to its unusual name,
which is an allusion to the Greek goddess that spins the
thread of life (24). The human Klotho gene, located on chromo-
some 13, can undergo alternative splicing in its third exon,
generating a secretable form with signaling properties (26).
The anchored Klotho protein is mostly present in the distal
convoluted tubules of the kidneys and the choroid plexus of
the brain but can be post-translationally processed and shed
into the blood, with the free extracellular domain functioning
as a hormone (27). One important physiological property
attributed to circulating Klotho is the initiation of a pathway
that inhibits insulin/IGF1 signaling (28). A moderate inhibi-
tion of insulin-like signaling is a conserved mechanism for
life extension (29), with evidence in humans that indicates
that the maintenance of average, physiological levels of the
insulin-like growth factor-1 among very old individuals can
contribute to a healthier endothelium and microcirculation
integrity (30).
The Klotho gene bears six single nucleotide polymorph-
isms (SNPs) in exon 2 and flanking regions, all in perfect
linkage disequilibrium, and two that result in substitutions
with functional importance (F352V, rs9536314 and C370S,
rs9527025), which are the notorious FC and VS haplotypes
(31,32). The minor VS variant of the human Klotho gene is
associated with an increased risk of vascular diseases (31,32).
The main aim of this study was to simultaneously investi-
gate the association among serum levels of C-reactive protein,
homocysteine and Klotho with classical risk factors and
previous vascular events in a sample of elderly subjects,
when considering covariates such as the usual intake of
macronutrients and the common Klotho haplotypes.
’ MATERIALS AND METHODS
Subjects and study design
This report consists of cross-sectional analyses with data
obtained from community-dwelling elderly women and men
of the urban outskirts of the Brazilian Federal District, aged
60 or over, to whom health screenings (medical, nutritional
and/or pharmacological) to assess their risk for vascular
events was indicated, conforming a cohort study known
as Prognosis and Therapeutics in Geriatrics (ProTeGer) in
Brasília, Brazil. Participation was voluntary, and informed
written consent was obtained from each subject. Data were
collected from August 2011 to July 2014 during consultations
in the Geriatric Service of the Catholic University Hospital.
For this analysis, the inclusion criteria were ageX60 years,
spontaneously seeking the service and to complying with
the medical protocol. Exclusion criteria included carriers
of autoimmune disease, chronic or recurrent infections, neo-
plastic diseases, chronic renal disease (creatinine clearance
o25 mL/min/1.73m2) and/or having used anti-inflamma-
tory drugs 30 days before clinical and biochemical tests.
This study was performed in accordance with the Declara-
tion of Helsinki guidelines on good clinical practices, and the
institutional ethical committee approved the study. No parti-
cipants were receiving nutritional guidance when laboratory
and clinical data were obtained.
Clinical procedures
Each subject was required to undergo biochemical, anthro-
pomorphic and clinical examinations prior to admission in
this study.
The medical evaluation included the investigation of prior
vascular events, including CAD, MI and stroke, based on
clinical history reported by the patient and/or companion.
All queries by the clinical practitioners that addressed prior
events were conducted with the support of information
already in the medical records or were based on comple-
mentary exams brought in by patient/companion to the
consultations. A case was rendered as presenting CAD when-
ever a procedure of cardiac catheterization had been indi-
cated by a professional elsewhere and had yielded findings
compatible with coronary artery occlusion. MI was identified
when the subject’s history included an admission to an
emergency service with clinical signs and symptoms of acute
infarction, as long as enzymatic [creatine kinase MB (CK-MB)
and troponin] and electrocardiographic evaluations were
recalled to support such endpoint. Compatible drug inter-
ventions, stenting or surgical revascularization, if recalled,
also accounted for the diagnosis of MI. Finally, stroke was
identified if the subject’s history or present state showed
signs and symptoms of an event and brain computerized
tomography image or cerebral angiogram was available to
confirm diagnosis. The occurrence of any vascular event was
computed only when independently declared in at least two
medical visits. For our analysis, subjects were segregated as
patients with or without previous vascular events.
The presence of comorbidities, such as high blood pres-
sure, dyslipidemia and type II diabetes mellitus, was diagnosed
based on the guidelines specific to each chronic condition,
and the continued use of drugs to control these conditions
was recorded. Practitioners of physical exercises were those
subjects who reported performing 30 minutes or more of
exercise at any level for at least four days a week (33), while
the smoking habit was defined as consumption of 4100
cigarettes over a lifetime (34).
Biochemical tests included the determination of serum
total cholesterol (TC) and fractions, triglycerides (TGL),
glycemia, glycated hemoglobin, insulin, thyroid-stimulating
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hormone (TSH), CRP, and homocysteine. At admission,
venous blood samples were drawn into EDTA-containing
tubes after a 12 h-overnight fasting period. Laboratory tests
were performed according to routine clinical analyses with
reagents from Boehringer Mannheim (Germany) and were
processed in an AutoHumalyzer device (Human GMBH,
Germany). The concentration of very low density lipoprotein
cholesterol (VLDL-c) was determined by dividing TGL levels
by 5, whereas the Friedewald equation was used to cal-
culate low density lipoprotein cholesterol (LDL-c) levels by
subtraction of both VLDL-c and high density lipoprotein
cholesterol (HDL-c) from TC. Cases were evaluated as
negative or positive to assemble categorical variables for
metabolic disorders. Lipid categorization was performed
according to NCEP ATP III (35), with each volunteer
identified as a carrier (or not) of mixed hyperlipemia
(TC X200 mg/dl, LDL-c X130 mg/dl and/or TGL X150 mg/dl).
Current use of antihyperlipidemic drugs was considered in
the definition of hyperlipidemia. Type 2 diabetes was defined
according to reference values established by the American
Diabetes Association (fasting glycemia X126 mg/dl) (36)
or the current use of oral hypoglycemic drugs or insulin.
Systolic and diastolic arterial blood pressure were measured
as recommended by the VI Brazilian Guidelines for Arterial
Hypertension (37). Patients with a systolic arterial blood
pressure of X140 mmHg and/or a diastolic arterial blood
pressure X90 mmHg, as well as those who were regularly
taking antihypertensive drugs, were classified as hyperten-
sive. The HOMA index was calculated based on the ratio of
the product of fasting insulin (mU/L) and fasting glucose
(mmol/L) by 22.5 (38).
Dietary evaluation
The present study evaluated the usual consumption of
macronutrients by the elderly women and men. A non-
consecutive three-day dietary record was completed that
included one weekend day. To fill out the forms correctly,
each patient received information from trained dieticians on
the number and sizes of food portions. To ensure the
completion of the dietary record, the nutrition staff provided
either personal or telephone assistance.
Seven to ten days after being distributed, the forms were
returned by patients during their next office visit, which was
scheduled to check the accuracy of the records and to com-
plete the information. The nutrient composition was analyzed
with the Diet Pro software, version 5i (A.S. Sistemas, Brazil),
adjusted for all available databases and complemented with
a chemical composition table for Brazilian foods (39). Sub-
jects whose records indicated the use of macronutrient-
containing supplementary material were excluded from
analyses.
After entry of dietary data, absolute intakes (mg) of
carbohydrates, protein and lipids were individually calcu-
lated. Absolute intakes were converted into relative calories
from these macronutrients in relation to total dietary intake,
also in calories, yielding variables referred to as dietary
intakes of carbohydrates (DIC), of lipids (DIL) and proteins
(DIP). Total energy intake (TEI) and the macronutrient
assessments were expressed as the mean daily intake based
on the 3-day dietary records.
To increase the reliability of data, the Brazilian Portuguese
version of the Mini-Mental State Examination (MMSE) (40)
was used. Patients were excluded from the analysis based on
the following scores according to educational levels:o13 for
illiterate individuals o17 for individuals with 1-7 years of
schooling, ando25 for individuals with eight or more years
of formal education (41).
Waist circumference (WC) was measured at the midpoint
between the last rib and the iliac crest during the individual’s
expiration (42).
Klotho Genotyping
A total of 10 ml of blood was collected by venipuncture
into tubes containing heparin; plasma was obtained by
refrigerated centrifugation (4oC) of 5 ml at 1,000 g for 15 min.
Plasma was aliquoted and immediately frozen at -20oC
until testing. DNA extraction used 5 ml of blood by the salt-
ing out method (44). The determination of FC and VS haplo-
types of the Klotho gene was performed as described by
Arking et al. (31), with modifications. Briefly, both poly-
morphic sites F352V (T/G; rs9536314) and C370S (G/C;
rs9527025) were amplified in the same DNA segment by
polymerase chain reaction (PCR), with forward 50 aggct-
catgccaaagtctgg 30 and reverse 50 gtttccatgatgaactttttgagg 30
primers. Amplification conditions consisted of hot start at
80oC for 1 min, followed by an initial denaturation at 94oC
for 2 min; 36 cycles consisted of incubation at 94oC for 40 s,
annealing at 60oC for 45 s and extension at 72o C for 50 s, and
the process was completed at 72oC for 5 min. Amplification
of the 505 pb products was confirmed by eletrophoresis in
1.6% agarose gels. When primer exhaustion was visually
verified, the polymorphic points were identified by direct,
automatized sequencing of amplification products in a 3130
DNA Analyzer system (Applied Biosystems, Foster City, CA,
USA), using the manufacturer’s reagents and procedures.
Sequencing reactions were performed using both forward
and reverse primers for the PCR step. Sequencing was recorded
as successful if a high quality sequence was obtained in at
least one direction.
Serum detection of Klotho
The Klotho protein concentration in serum was determined
by ELISA (Enzyme-linked Immunosorbent Assay) using a
specific kit produced by the BlueGenes Biotech company
(Shangai, China) with an analytic sensitivity of 0.1 ng/mL,
according to the manufacturer’s instructions. All samples
were analyzed in duplicate, while standard curve points
were produced in triplicate. Readings were generated using
a BioTek Absorbance Reader, ELx800 model (Winooski, VT,
USA). The intra-assay variation coefficients ranged from
3.1 to 9.5%, with all inter-assay variation coefficients
below 5.0%.
Statistical analysis
Student’s t-test was used to test the influence of Klotho
haplotypes on continuous anthropometric, clinical and bio-
chemical variables. Then, to evaluate the occurrence and
strength of the association of circulating levels of Klotho and
of other classic biomarkers (C-reactive protein and homo-
cysteine) with prior vascular events, correlation coefficients
were obtained between the investigated serum biomarkers
and the continuous and categorical anthropometric, clinical
and biochemical variables of potential confounding effects in
the main model. The close-to-normal distribution of all con-
tinuous variables was assessed using the Kolmogorov-
Smirnov test. The association between continuous variables
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was evaluated using the Pearson’s correlation test, whereas
the involvement of a least one categorical variable in the model
was assessed using Spearman’s counterpart, with men and
women represented by 1 or 2 and the absence or presence of
a feature represented by 0 or 1, respectively. Whenever an
interaction was noticed, the association of the biomarkers
with the vascular events was tested by means of partial
correlation analyses with an adjustment for the confounding
variable(s) or condition(s). In addition, raw concentrations of
each biomarker were tested across individuals who had or
had not experienced an acute MI (AMI) prior to the study
onset using the Student’s t-test, with a sequential ANOVA
(logistic regression model) used to confirm a significant
association. When results are significantly different, the effect
sizes (d) and respective confidence intervals (95% CIs) are
presented. Stepwise linear multivariate regression analysis
was performed to assess the extent to which serum con-
centrations of the biomarkers could explain the variability in
occurrence of the vascular events.
All analyses were performed with the Statistical Package
for the Social Sciences (SPSS) for Windows (version 17.0). For
this study, the standard two-tailed threshold for significance
(pp0.05) was adjusted following the Bonferroni’s correction
for multiple comparisons when a trait is tested across k
independent variables (eg., for k=10 tests, ap0.005).
’ RESULTS
After clinical-laboratory and dietary assessments and
the verification of the inclusion and exclusion criteria, the
eligible sample for analyses was composed of 168 elderly
patients with a mean age of 73.1 years. In terms of the F352V
polymorphism, 138 (82.1%) of the subjects were FF homo-
zygotes, whereas 27 (16.1%) had the FV genotype and 3 (1.8%)
had the VV genotype. The exact same proportions were
found for the CC, CS and SS genotypes, with firm cor-
respondence between F and C carriage and between V and S
presence in each individual genotype, which is consistent
with a perfect linkage disequilibrium across these two SNPs
in our sample. This finding is highly consistent with the
assumption of Arking and colleagues, who stated that the
identification of the F352V variation per se can be used as a
surrogate for the determination of the whole haplotype for
epidemiological purposes (43).
Table 1 presents the results of an inferential analysis of
the results, which investigated the associations between the
Klotho haplotype and the leading clinical-laboratory vari-
ables determined in the sample. In clinical terms, the sample
characterization revealed that a relatively low proportion
of subjects had previous vascular events, but there was
a significant prevalence of metabolic disorders that was
compatible with a profile that was eligible for primary pre-
vention. The analysis showed no association of haplotypes
with any of the basic variables. In addition, there were no
differences in the prevalence of prior CAD, stroke and AMI
cases among the haplotype groups.
The possibility of the association of clinical-laboratory and
dietary variables with circulating Klotho levels was verified
using correlation tests (Table 2), where traditional serum
markers for vascular events (CRP and homocysteine) were
considered. In this context, serum CRP and homocysteine
levels were significantly influenced by gender, the average
Table 1 - Anthropometric, clinical and metabolic variables of the sample.
Groups
Variables All (n = 168) FC/FC (n = 138) ___/VS (n = 30) p
Male, % 39.9 37.7 50.0 0.212
Age, years 73.1±9.0 73.0±8.7 73.7±10.1 0.677
WC, cm 97.4±11.5 98.0±11.8 95.2±9.9 0.204
Glucose level, mg.dl-1 103.2±27.7 104.4±29.9 98.2±13.2 0.082
HbA1c, % 5.9±1.0 5.9±1.1 5.7±0.6 0.280
Insulin, mUI/mL 9.3±10.0 9.7±10.8 7.3±4.9 0.230
HOMA index 2.6±3.8 2.8±4.1 1.8±1.2 0.163
DM2y, % 22.6 26.1 6.7 0.021
Total cholesterol, mg.dl-1 193.4±39.9 192.3±36.2 198.8±50.1 0.404
LDL-c, mg.dl-1 115.3±33.7 114.4±33.1 119.6±37.0 0.448
Triglycerides, mg.dl-1 141.2±64.7 143.3±62.1 131.6±75.8 0.370
Hyperlipemiay, % 51.8 50.7 56.7 0.438
HDL-c, mg.dl-1 48.1±10.9 47.5±10.6 50.8±12.2 0.135
SBP, mm Hg 134.8±19.5 134.8±19.5 134.5±19.8 0.927
DBP, mm Hg 80.6±11.1 80.6±11.1 80.8±11.8 0.918
SAHy, % 77.4 78.3 73.3 0.559
CRP, mg.dl-1 3.5±5.6 3.7±5.8 2.6±4.3 0.339
TSH, mIU.l-1 2.5±2.2 2.6±2.3 2.2±1.6 0.294
Homocysteine, mmol.l-1 12.8±8.8 12.5±8.7 14.0±9.1 0.413
Previous strokey, % 9.5 10.9 3.3 0.202
Previous AMIy, % 4.2 4.3 3.3 0.801
Previous CADy, % 1.8 2.2 - 0.415
Sedentaryy, % 60.7 61.6 56.7 0.616
Smokery, % 37.3 36.5 41.4 0.621
klotho, ng.ml-1 1.2±0.6 1.2±0.6 1.2±0.8 0.743
Data are expressed as average±standard deviation for continuous parameters or relative frequencies for categorical features. Student’s t test or the
chi-squareytest were used. WC = waist circumference; HbA1c = glycated hemoglobin A1c; HOMA = Homeostatic model assessment; DM2 = type 2 diabetes
mellitus; LDL-c = low density lipoprotein cholesterol; HDL-c = high density lipoprotein cholesterol, SBP = systolic blood pressure; DBP = diastolic blood
pressure; SAH = systemic arterial hypertension; CRP = C-reactive protein; TSH = thyroid-stimulating hormone; AMI = acute myocardial infarction; CAD =
coronary artery disease. Significance threshold set at pp0.002 according to the Bonferroni correction.
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level of CRP was 87% higher among women [p=0.012; d=0.23
(0.1; 0.4)] and homocysteine levels were 34% higher in men
[p=0.020; d=-0.25 (-0.4; -0.1)]. In addition, sedentary indivi-
duals exhibited a 75% higher mean serum CRP level
[p=0.044; d=0.23 (0.1; 0.4)] compared with physically active
individuals. Apart from these associations, our correlation
analyses revealed no other significant association between
the three serum biomarkers and any of the clinical, bio-
chemistry and dietary features that were investigated. There-
fore, Klotho levels do not appear to be influenced by
demographic aspects, lifestyle factors or the comorbidities
presented by patients in a context that was compatible with
primary care settings. Accordingly, macronutrient intake was
not significantly correlated with any of the serum markers
that were considered.
Correlation analyses were then performed to investigate
the association of CRP, homocysteine and Klotho biomarkers
with the occurrence of previous vascular events (CAD,
MI and stroke) at baseline (Table 3). These analyses were
controlled for the presence of confounding factors (gender
and physical inactivity) that had been previously associated
with some biomarkers, and the main result consisted of a
positive association between circulating Klotho levels and a
prior AMI. When the serum levels of CRP, homocysteine and
Klotho were compared among subjects, Klotho was the
only marker to display different levels [72% higher among
individuals affected by MI; po0.001; d=1.6 (0.9 – 2.6)]
according to a previous history of AMI (Figure 1). This
association was confirmed by means of a sequential ANOVA
with ten selected confounding factors of a discrete nature
(age, WC, HOMA index, total cholesterol, triglycerides, SBP,
DBP, TSH, CRP and homocysteine) that were tested along-
side Klotho levels.
The analysis of multiple classic clinical, anthropometric
and biochemical risk factors for vascular events along with
circulating mediators via stepwise multivariate regression
showed that the Klotho level was the single most predictive
variable in the model (R2=0.086), and accounted for 29.3% of
the variance in occurrence of AMI in the sample. At present,
this result suggests an association and should be validated in
another independent sample.
’ DISCUSSION
Our study suggests that serum Klotho could be an inde-
pendent marker for post-event MI among elderly indivi-
duals, with possible implications for secondary prevention,
given the enhanced levels of the mediator among the affected
outpatients. To our knowledge, this is the first report to
identify this association. However, serum Klotho levels have
been associated with different vascular risk factors in humans,
such as atherosclerosis, oxidative stress and endothelial
Table 2 - Correlation analyses of raw serum levels of C-reactive protein, homocysteine and Klotho across clinical, biochemical and
healthcare features of the 168 older subjects at admission.
Age Gendery SBP DBP SAHy aSAHy
CRP 0.09; 0.242 0.23; 0.002# -0.07; 0.399 -0.10; 0.195 0.09; 0.268 0.09; 0.238
Homocysteine 0.18; 0.022 -0.25; 0.001d -0.10; 0.203 -0.18; 0.022 0.05; 0.544 0.07; 0.373
Klotho 0.11; 0.178 0.06; 0.424 -0.18; 0.025 -0.16; 0.041 -0.06; 0.473 -0.05; 0.538
WC Sedentaryy HbA1c HOMA DM2y aDM2y
CRP 0.08; 0.289 0.23; 0.002f -0.07; 0.400 0.20; 0.010 0.05; 0.492 0.01; 0.873
Homocysteine 0.02; 0.791 0.11; 0.165 -0.02; 0.764 0.01; 0.933 0.09; 0.233 0.01; 0.884
Klotho -0.05; 0.524 0.07; 0.375 -0.07; 0.353 -0.07; 0.404 -0.01; 0.898 0.03; 0.660
TC LDL-c TGL hyperlipidemia HDL-c alipemiay
CRP 0.03; 0.722 -0.06; 0.433 -0.01; 0.887 0.03; 0.686 -0.03; 0.687 -0.01; 0.968
Homocysteine -0.12; 0.119 -0.06; 0.474 -0.03; 0.672 -0.06; 0.476 -0.09; 0.233 0.06; 0.405
Klotho -0.18; 0.021 -0.10; 0.204 -0.05; 0.537 -0.01; 0.935 -0.06; 0.444 -0.02; 0.802
Drinkery Smokery DIC DIL DIP TEI
CRP 0.12; 0.108 0.13; 0.098 -0.05; 0.610 -0.04; 0.697 0.18; 0.050 -0.04; 0.673
Homocysteine 0.17; 0.025 0.12; 0.134 -0.13; 0.161 0.13; 0.179 0.07; 0.484 0.01; 0.924
Klotho 0.02; 0.790 0.14; 0.086 0.10; 0.277 -0.19; 0.045 0.12; 0.193 -0.20; 0.031
The Pearson’s and the Spearman’sy correlation tests were used. For the latter, the presence or absence of a feature was represented by a 1 or a 0,
respectively. Data are expressed in correlation indexes and significance level (r; P). a = use of therapeutic drugs for the condition; WC = waist circum-
ference; SBP = systolic blood pressure; DBP = diastolic blood pressure; TC = total cholesterol; HDL-c = high density lipoprotein cholesterol; HOMA =
Homeostatic model assessment; HbA1c = glycated hemoglobinA1c; SAH = systemic arterial hypertension; DM2 = type 2 diabetes mellitus; DIC = dietary
intake of carbohydrates; DIL = dietary intake of lipids; DIP = dietary intake of proteins; TEI = total energy intake. The significance threshold was set at
pp0.002 after adjustment using the Bonferroni correction. Superscript #, d and f refer to effect sizes (d) and 95% confidence intervals (in parenthesis) of
0.23 (0.1; 0.4), -0.25 (- 0.4; -0.1) and 0.23 (0.1; 0.4), respectively.
Table 3 - Correlation analyses of raw serum levels of C-reactive
protein, homocysteine and Klotho across carriers and non-carriers
of vascular events that occurred prior to admission in the study.
Vascular events
Stroke AMI CAD
CRP w,= 0.14; 0.066 0.04; 0.615 -0.06; 0.465
homocysteine w 0.12; 0.124 0.01; 0.902 0.01; 0.911
Klotho 0.07; 0.381 0.22; 0.006# -0.13; 0.100
The Spearman’s and the Partial (for adjustments) correlation tests were
used and were adjusted for wgender and/or =physical activity when appro-
priate. The presence or absence of a feature was represented by a 1 or a 0,
respectively. Data are expressed as correlation indexes and significance
levels (r; P). AMI = acute myocardial infarction; CAD = coronary artery
disease. The significance threshold was set at pp0.016 after adjustment
using the Bonferroni correction. Superscript # refers to an effect size of
0.22 and a 95% confidence interval of (0.1; 0.4).
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dysfunction (24,25,44,45). Most findings in the literature
suggest a role for serum Klotho in the susceptibility to
vascular, metabolic-born disorders. Intriguingly, our analyses
on qualitatively and quantitatively portrayed metabolic traits
(pressoric, lipemic, glycemic) of older adults across Klotho
haplotypes or levels showed no significant associations. In
addition, no associations were found in classic anthropo-
metric measures, lifestyle features or health care practices. In
our setting, this evidence suggests that Klotho does not relate
to (and may not be an actual player in) the development of
vascular disorders and events. Instead, we hypothesize that
Klotho may be a previously unnoticed pathophysiological
element that is linked to the cardiac post-MI state.
Ventricular dilation occurs during the acute phase (ventri-
culomegaly) of MI, and late cavitary dilation can occur due
to eccentric hypertrophy (46,47). These dilations are adapta-
tion processes in which the heart tends to assume a spherical
shape due to the redistribution of forces for the maintenance
of ventricular function as opposed to increased parietal stress
(greater parietal tension in diastole than in systole) (48-50).
Hypertrophied hearts in animal models show an increased
expression of TRPC6 channels (transient receptor potential
canonical 6), whose expression is regulated by different ten-
sions and intensities. Soluble Klotho inhibits TRPC6 cardiac
channels and thus protects the myocardium against exces-
sive/pathological remodeling (51). Thus, high Klotho levels
may appear post-infarction as an adaptation to this event in
humans, supporting the finding of our study.
In favor of a rationale that supports the compensatory prop-
erties of Klotho after MI, adenovirus-mediated delivery of
the gene into animal model ameliorates vascular endothelial
dysfunction and prevents myocardial medial hypertrophy
(44,52). However, no prior studies have associated serum
Klotho levels in infarcted humans.
In addition to the functions already mentioned, Klotho can
also act on the maturation of adipocytes and glucose metab-
olism. Klotho knockout rats are resistant to obesity even
when exposed to a high fat diet (53,54), revealing a clear
synergy between the soluble marker and diet. To control for
these potential covariates, the total caloric intake and the
proportional intake of macronutrients acquired from the
usual diet were investigated in our study. However, our
results indicate that there is no significant interaction between
dietary profile and serum Klotho levels. Thus, the possibility
that intake pattern was responsible for diet-related variations
in the mediators was ruled out.
Although patients with major infarction-related myo-
cardial remodeling show a progressive worsening of cardiac
function, there is still no reliable marker for such a process,
and slowing or reversing remodeling remains a challenge in
the clinical care of post-MI subjects. However, few are the
studies on new, reliable markers, and controversy (if any)
may arise from the presence of confounding factors that were
not adequately investigated or controlled. In this regard, our
work has revealed that circulating Klotho levels did not vary
under the influence of classic risk factors for vascular events
(eg., glycemic and lipemic profiles), healthcare measures or
demographic aspects like other biomarkers currently used in
clinical practice (CRP and homocysteine). We were unable to
rule out from our analysis subjects who consumed blood
pressure-, glucose- or lipid-lowering drugs (485% of the
sample). However, our analyses demonstrated that these
therapies did not alter any of the biomarkers that were
investigated. There are limitations in our study that are
worth mentioning. This was a cross-sectional study, and the
fact that the clinical data relied mostly on the history of
health events may lead to biases related to memory and the
ability to recall. Temporal influence on the levels of serum
markers cannot be discarded because the onset of the
Figure 1 - Comparisons of raw circulating levels of C-reactive
protein (A), Homocysteine (B) and Klotho (C) in individuals who
had or had not experienced a prior acute myocardial infarction
(AMI). Significance was verified by Student’s t-test for independent
samples and was confirmed by sequential ANOVA. Vertical bars
represent intervals of one standard deviation. Superscript # repre-
sents an effect size of 1.6 and a 95% confidence interval of (0.9; 2.6).
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vascular events was not analyzed. In addition, the overall
number of subjects was limited to detect small differences in
the associations investigated. For example, our results did
not show significant MI-related differences of CRP levels,
a post hoc power analysis indicated that only a sample of
1116 individuals would suffice to provide power [d=0.20
(-0.19; 0:59)] to detect small differences in this variable. In
terms of Klotho levels, it is outstanding that a reasonable
effect size was reached in the correlational analysis [d=0.22
(0.1 – 0.4)] of our sample size of 168 subjects. Therefore, the
results of our study could be interpreted as having fairly
adequate power to detect meaningful differences.
Our results show that the serum Klotho concentration is
higher in individuals with a clinical history of MI, but not in
individuals with a history of CAD or stroke. Classic risk
factors for vascular diseases were not associated either serum
Klotho levels or the main genetic variations of Klotho. The
augmented levels of Klotho post-infarction may reflect a
compensatory mechanism to prevent pathological myocar-
dial hypertrophy. However, further studies with an appro-
priate, prospective design are needed to evaluate the
pathophysiological mechanisms of serum Klotho fluctuation
in post-event settings.
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